Literature DB >> 8056053

Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism.

S Horiuchi1, Y Koyanagi, Y Zhou, H Miyamoto, Y Tanaka, M Waki, A Matsumoto, M Yamamoto, N Yamamoto.   

Abstract

To detect transcripts encoding the interleukin-6 receptor (IL-6R) molecule lacking the transmembrane (TM) domain, in various cell lines and peripheral blood mononuclear cells (PBMC), we used the polymerase chain reaction (PCR) with primer pairs that flank the TM domain and which were selected to generate a 398-bp fragment. We detected 398-bp and 304-bp DNA molecules in the PCR products of the U1, J22HL60, MT-2, MT-4, U937 and HL60 cell lines and of PBMC isolated from several individuals. The sequencing analysis of both DNA molecules showed that a 94-bp region consisting of the TM domain of IL-6R was deleted in the 304-bp molecule. Moreover, we detected a soluble (s) IL-6R protein of 45 kDa in culture supernatants of the MT-2, MT-4 and U937 cell lines by radioimmunoprecipitation using specific antibodies against sIL-6R. Our results indicate that active deletion of the TM domain by alternative splicing of mRNA represents one mechanism for release of sIL-6R into the culture supernatants of cells, or into serum or urine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8056053     DOI: 10.1002/eji.1830240837

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  56 in total

1.  Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.

Authors:  J N Varghese; R L Moritz; M-Z Lou; A Van Donkelaar; H Ji; N Ivancic; K M Branson; N E Hall; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

2.  An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Authors:  Owen W Stephens; Qing Zhang; Pingping Qu; Yiming Zhou; Shweta Chavan; Erming Tian; David R Williams; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

3.  Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Authors:  C Toniatti; A Cabibbo; E Sporena; A L Salvati; M Cerretani; S Serafini; A Lahm; R Cortese; G Ciliberto
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

4.  IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes.

Authors:  Sarah Y Lee; Irina A Buhimschi; Antonette T Dulay; Unzila A Ali; Guomao Zhao; Sonya S Abdel-Razeq; Mert O Bahtiyar; Stephen F Thung; Edmund F Funai; Catalin S Buhimschi
Journal:  J Immunol       Date:  2011-01-31       Impact factor: 5.422

5.  Altered interleukin-2 receptor alpha-chain is expressed in human T-cell leukaemia virus type-I-infected T-cell lines and human peripheral blood mononuclear cells of adult T-cell leukaemia patients through an alternative splicing mechanism.

Authors:  S Horiuchi; Y Koyanagi; Y Tanaka; M Waki; A Matsumoto; Y W Zhou; M Yamamoto; N Yamamoto
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

6.  Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha.

Authors:  V Modur; Y Li; G A Zimmerman; S M Prescott; T M McIntyre
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 7.  IL-6 biology: implications for clinical targeting in rheumatic disease.

Authors:  Leonard H Calabrese; Stefan Rose-John
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

8.  The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.

Authors:  Paul Baran; Selina Hansen; Georg H Waetzig; Mohammad Akbarzadeh; Larissa Lamertz; Heinrich J Huber; M Reza Ahmadian; Jens M Moll; Jürgen Scheller
Journal:  J Biol Chem       Date:  2018-03-20       Impact factor: 5.157

9.  High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy.

Authors:  S Horiuchi; W Ampofo; Y Koyanagi; A Yamashita; M Waki; A Matsumoto; M Yamamoto; N Yamamoto
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

10.  Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer.

Authors:  Y Okugawa; C Miki; Y Toiyama; H Yasuda; T Yokoe; S Saigusa; J Hiro; K Tanaka; Y Inoue; M Kusunoki
Journal:  Br J Cancer       Date:  2010-09-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.